Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4918 - PATINA: A Randomized Open Label Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti HER2 therapy + Endocrine Therapy vs Anti HER2 therapy + Endocrine Therapy after induction treatment for Hormone Receptor Positive, HER2-Positive Metastatic Breast Cancer


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Breast Cancer


Otto Metzger


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


O. Metzger1, S. Mandrekar2, E. Ciruelos3, S. Loibl4, P. Valagussa5, A.M. Demichele6, E. Lim7, D. Tripathy8, E.P. Winer1, C. Huang9, M. Khoeler9, L. Carey10, P. Francis11, K. Miller12, S. Goel1, M.P. Goetz13, A. Prat14, S. Loi15, I. Krop1, L. Gianni16

Author affiliations

  • 1 Medical Oncology, Dana Farber Cancer Institute, 02215 - Boston/US
  • 2 Biostatistics, Mayo Clinic AFT SDC, Rochester/US
  • 3 Medical Oncology, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 4 Medical Oncology, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg/DE
  • 5 Medical Oncology, Fondazione Michelangelo, Milan/IT
  • 6 Medical Oncology, University of Pennsylvania-Perelman Center for Advanced Medicine, 19104 - Philadelphia/US
  • 7 Medical Oncology, Garvan Institute, Sydney/AU
  • 8 Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 9 Medical Oncology, Pfizer, New York/US
  • 10 Medical Oncology, University of North Carolina - Chapel Hill, 27599 - Chapel Hill/US
  • 11 Medical Oncology, Peter MacCallum Cancer Center, 3002 - Melbourne/AU
  • 12 Medical Oncology, Indiana University Simon Cancer Center, 46202 - Indianapolis/US
  • 13 Medical Oncology, Mayo Clinic, Rochester/US
  • 14 Medical Oncology  , Hospital Clinic, 8036 - Barcelona/ES
  • 15 Translational Breast Cancer Genomics Lab, Division Of Research, Peter MacCallum Cancer Center, 3002 - Melbourne/AU
  • 16 Medical Oncology, IRCCS San Raffaele, 20132 - Milan/IT


Abstract 4918


Pre-clinical data and initial results from clinical studies point to the added benefit of CDK4/6 inhibition when combined with anti-HER2 tx. The current study is designed to evaluate the added benefit of Palbociclib when given in combination with anti-HER2 and endocrine tx maintenance in the 1st line setting of metastatic HER2+HR+ breast cancer.

Trial design

PATINA is an international, open-label, pivotal Phase III study. Primary objective is to demonstrate that the combination of Palbociclib with anti-HER2 plus endocrine tx is superior to anti-HER2 plus endocrine tx in prolonging PFS. Sample size is 496 pts. The study starts after completion of 6-8 cycles of chemotherapy-containing anti-HER2 tx for metastatic breast cancer in the 1st line setting. Pts are eligible provided they are without evidence of disease progression by local assessment (i.e. CR, PR or SD). To account for the need for less intense tx regimens for a subset of pts diagnosed with HER2+ER+ disease, clinicians may recommend the combination of trastuzumab with either a taxane or vinorelbine prior to study initiation. Clinicians might also choose a non-Pertuzumab option for pts previously treated with pertuzumab in the neo(adjuvant) setting. Secondary objectives include measures of tumor control (OR, CBR, DOR), OS, safety and QOL. The translational science main objective is to compare PFS estimates according to PIK3CA mutation status assessed by cfDNA analysis. Endocrine tx options are AI or fulvestrant. Premenopausal pts must receive ovarian suppression. The study has a 90% power to detect a hazard ratio of 0.667 in favor of the palbociclib arm. Pts approached to participate in AFT-38 will be asked to indicate on the informed consent forms whether remaining biospecimens and clinical data from the control arm of the study can be shared with the Mastering Breast Cancer (MBC) Initiative. The overarching purpose of the MBC is to create a mechanism for understanding the natural history of metastatic breast cancer by cataloguing longitudinally studied tumor-specific markers and treatment effects.

Clinical trial identification


Legal entity responsible for the study

Alliance Foundation Trials




C. Huang: Employee Pfizer Inc. M. Khoeler: Employee and shareholder Pfizer Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.